When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Journal Editorial Report: The Fed Chief signals rate cuts are coming. As we saw during the Covid pandemic, lab-created experiments can wreak havoc when they escape their confines. Once released, they ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

Artificial intelligence has become an invisible assistant, quietly shaping how we search, scroll, shop, and work. It drafts our emails, curates our feeds, and increasingly guides decisions in ...

In a new paper with implications for preventing Alzheimer's disease and other neurological disorders, Keith Hengen, an associate professor of biology in Arts & Sciences at Washington University in St.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Lymphocyte activation gene 3 (LAG3) is an immune checkpoint receptor involved in the regulation of T cell activation and function that has emerged as a promising immunotherapeutic target. Although one ...